Our research aims to improve the efficacy of standard of care immunotherapy, chemotherapy and radiotherapy in human solid cancers by understanding the molecular mechanisms underlying tumour stromal contributions to tumour growth and therapy efficacy.
I am involved in some projects that are focused in the stroma components of a tumour, particularly the endothelial vessels, and its potential role in some key processes including chemotherapy or metastasis.
My research focuses on how we can therapeutically target integrins to modulate angiogenesis in heart failure.
My work will identify other players in the regulation of angiocrine signalling using a CRISPR screen. I will also explore the molecular mechanisms underlying how FAK controls angiocrine signalling.
My project looks at the modelling of cancer for improved therapy development. I am carrying out in vivo cancer experiments, with and without modifications of the tumour microenvironment, to examine effects of such treatments on anti-cancer therapy efficacy.